Navigation Links
Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
Date:10/6/2010

PARSIPPANY, N.J., Oct. 6 /PRNewswire/ -- Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA™ (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue of the peer-reviewed journal, Obstetrics & Gynecology.  The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.  It is estimated that up to 22 million women suffer from HMB in the U.S.(1,2)

In the double-blind, placebo-controlled 6-month study, women ages 18-49 years with HMB, defined as mean menstrual blood loss of 80 mL or more per cycle, were randomized to receive LYSTEDA (3.9 g/d) (n=115) or placebo (n=72) for up to 5 days per menstrual cycle through six cycles.  The LYSTEDA group had a significantly greater reduction in menstrual blood loss of 69.6 mL (40.4%) compared with 12.6 mL (8.2%) in the placebo group (p<.001).  This reduction in menstrual blood loss was considered meaningful to women.  Women taking LYSTEDA also experienced significant improvements in limitations in social, leisure and physical activities, measured using the Menorrhagia Impact Questionnaire (MIQ), a validated patient-reported outcome instrument, to measure changes at baseline and after three treatment menstrual cycles.

LYSTEDA was generally well tolerated, and the majority of adverse events were mild to moderate in severity.  The most common adverse events reported were menstrual discomfort or cramps, headache, and back pain.

"We are excited by the results of this clinical trial.  Women receiving LYSTEDA met all three primary efficacy points: a significantly greater reduction in menstrual blood loss compared with placebo, a reduction exceeding a pre-specified volume, and most importantly, a reduction
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
2. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
3. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
8. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
9. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
10. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
11. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... August 27, 2015 According to a new ... Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage ... 2020", published by MarketsandMarkets, the Medical Lifting Sling Market is poised ... in 2015, at a CAGR of 11.4 % from 2015 to ... ma rket data T ables and 65 ...
(Date:8/27/2015)... --  Women Grow , the fastest-growing professional networking organization for ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... educational sessions. CWCBExpo in LA will take place September 16-18, ... Center in Los Angeles, CA , and ... the marijuana industry. The Women Grow tracks at ...
(Date:8/27/2015)... Aug. 27, 2015  A mere one in seven ... Allen Hamilton . A new white paper ... are impeding and disrupting manufacturers, success. The ... Improve Value In Product Development Processes provides insight ... and how it affects the product development process resulting ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... no stent thrombosis or MACE,after one year, ... 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation today,welcomed the ... FIRST, II,and III Clinical Trials, reaffirming prior ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System and XIENCE(TM) V ...
... of Choroidal,Neovascularization (CNV) in an AMD Model, SAN ... ,the category leader in therapeutic agents against bioactive ... of human age-related macular degeneration (AMD). , The ... the,Association of Research in Vision and Ophthalmology (ARVO) ...
Cached Medicine Technology:SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions ... it should begin with the employer and employees getting together for meaningful group ...
(Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
(Date:8/28/2015)... ... ... Mendon, IL, home of the Adams County Fairgrounds, was treated once again to ... In its second year, the “Music With A Mission” benefit concert was held there ... “Music With A Mission” is to raise money to help fund music education programs ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ... is now selling External Counterpulsation (EECP or ECP) machines with a full clinic licence ... been in business since 2007 helping people prevent and reverse heart disease ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... tailor therapy regimen to individuals, experts say , , TUESDAY, ... affect the way children respond to treatment for lymphoblastic ... children suffering from this type of blood and bone ... to treatment. Now researchers think they know why. , ...
... radiation indicates need for earlier screening, study notes, , , ... female childhood cancer survivors under the age of 40 ... are not following the recommended advice to get screening ... The recommendation suggests starting screening mammograms at age 25, ...
... Ill., Jan. 27 EngagementHealth, LLC., an innovator ... launch of its comprehensive disease prevention and health ... RBNF ). Rurban Financial is a leading ... services, and bank data and item processing, headquartered ...
... point-of-use and central pharmacy automation solutionsMOUNTAIN VIEW, Calif., Jan. ... a leading provider of system solutions to acute healthcare ... by Emory Healthcare for Omnicell point-of-use and central pharmacy ... (NASDAQ: OMCL ) is a leading provider ...
... 27, 2009 Environmental Tobacco Smoke (ETS) commonly called ... account for complications during pregnancy and birth. It is ... than do whites from smoking and ETS exposure. In ... the American Journal of Preventive Medicine , researchers ...
... Jan. 27 Trust for America,s Health (TFAH) applauds ... funding to improve the health of Americans while stimulating ... "This funding is desperately needed to revitalize and ... be putting more Americans to work in programs that ...
Cached Medicine News:Health News:In Kids, Genes May Affect Leukemia Treatment 2Health News:In Kids, Genes May Affect Leukemia Treatment 3Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF) 2Health News:Avoiding secondhand smoke during pregnancy 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 3
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Novus 3000 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Medicine Products: